Paper307692
Control of normal cell differentiation and the phenotypic reversion of malignancy in myeloid leukaemia.
Sachs L. Nature, 1978. Cited by 649 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Control of normal cell differentiation and the phenotypic reversion of malignancy in myeloid leukaemia. Papers, record 307692. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/307692
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Control of normal cell differentiation and the phenotypic reversion of malignancy in myeloid leukaemia.
- PubMed
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cell Differentiation | Major topic |
| Colony-Stimulating Factors | Major topic |
| Glycoproteins | Major topic |
| Granulocytes | Major topic |
| Hematopoietic Stem Cells | Major topic |
| Leukemia, Myeloid | Major topic |
| Leukocytes | Major topic |
| Macrophages | Major topic |
| Animals | |
| Bone Marrow Cells | |
| Cell Membrane | |
| Cells, Cultured | |
| Chromosome Aberrations | |
| Chromosome Disorders | |
| Dexamethasone | |
| Humans | |
| Leukemia, Experimental | |
| Lipid A | |
| Mice |
Source PubMed
Cited by102
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 649 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,232,986 | Differentiation therapy in acute myeloid leukaemia: molecular basis, clinical progress, and future perspectives. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42232986 | PubMed |
| 40,777,043 | The immunomodulatory role of tumor-initiating cells in digestive system tumors: from mechanisms to therapy. | Front Immunol | 2025 | https://conductscience.org/library/papers/40777043 | PubMed |
| 39,692,941 | Impact of prolactin treatment on enhancing the cellular responses of MCF7 breast cancer cells to tamoxifen treatment. | Discov Oncol | 2024 | https://conductscience.org/library/papers/39692941 | PubMed |
| 37,168,856 | ATRA treatment slowed P-selectin-mediated rolling of flowing HL60 cells in a mechano-chemical-dependent manner. | Front Immunol | 2023 | https://conductscience.org/library/papers/37168856 | PubMed |
| 36,980,800 | A Novel Family of Lysosomotropic Tetracyclic Compounds for Treating Leukemia. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/36980800 | PubMed |
| 34,938,986 | History of Acute Promyelocytic Leukemia. | Clin Hematol Int | 2021 | https://conductscience.org/library/papers/34938986 | PubMed |
| 34,193,815 | Acute promyelocytic leukemia current treatment algorithms. | Blood Cancer J | 2021 | https://conductscience.org/library/papers/34193815 | PubMed |
| 33,958,005 | Tumor reversion: a dream or a reality. | Biomark Res | 2021 | https://conductscience.org/library/papers/33958005 | PubMed |
| 33,446,633 | Prolactin receptor-driven combined luminal and epithelial differentiation in breast cancer restricts plasticity, stemness, tumorigenesis and metastasis. | Oncogenesis | 2021 | https://conductscience.org/library/papers/33446633 | PubMed |
| 33,050,159 | Targeting SRC Kinase Signaling in Pancreatic Cancer Stem Cells. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/33050159 | PubMed |
| 32,824,945 | Nuclear Receptors as Potential Therapeutic Targets for Myeloid Leukemia. | Cells | 2020 | https://conductscience.org/library/papers/32824945 | PubMed |
| 32,700,196 | Acute Promyelocytic Leukemia: A History over 60 Years-From the Most Malignant to the most Curable Form of Acute Leukemia. | Oncol Ther | 2019 | https://conductscience.org/library/papers/32700196 | PubMed |
| 29,337,961 | How the evolution of multicellularity set the stage for cancer. | Br J Cancer | 2018 | https://conductscience.org/library/papers/29337961 | PubMed |
| 26,911,190 | Leukaemia 'firsts' in cancer research and treatment. | Nat Rev Cancer | 2016 | https://conductscience.org/library/papers/26911190 | PubMed |
| 25,821,840 | The "virgin birth", polyploidy, and the origin of cancer. | Oncoscience | 2015 | https://conductscience.org/library/papers/25821840 | PubMed |
| 25,387,435 | Towards a systemic paradigm in carcinogenesis: linking epigenetics and genetics. | Mol Biol Rep | 2015 | https://conductscience.org/library/papers/25387435 | PubMed |
| 24,938,378 | Progress in the treatment of acute promyelocytic leukemia: optimization and obstruction. | Int J Hematol | 2014 | https://conductscience.org/library/papers/24938378 | PubMed |
| 24,469,826 | Pioneer of hematopoietic colony-stimulating factors: Leo Sachs (1924-2013). | Proc Natl Acad Sci U S A | 2014 | https://conductscience.org/library/papers/24469826 | PubMed |
| 24,264,602 | ERK5 pathway regulates transcription factors important for monocytic differentiation of human myeloid leukemia cells. | J Cell Physiol | 2014 | https://conductscience.org/library/papers/24264602 | PubMed |
| 23,521,217 | Re-expression of microRNA-150 induces EBV-positive Burkitt lymphoma differentiation by modulating c-Myb in vitro. | Cancer Sci | 2013 | https://conductscience.org/library/papers/23521217 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/307692
GET https://conductscience.org/api/papers/v1/307692/cited_by?page=2